News

Registration Now Open for Catalyst Life Sciences Conference

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), announced that registration is open for the Catalyst Life Sciences Conference. The event will be held October 6-7, 2022 at the Omni Hotel in  Richmond, Virginia.

This conference is designed for scientists, engineers, entrepreneurs, incubators and biohubs, life science companies, technology transfer departments and economic development departments. The format consists of expert panels sharing their knowledge and engaging in dialog with the audience.

Joni L. Rutter, Ph.D. will be a keynote speaker. Dr. Rutter is the Acting Director of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). NCATS was established to transform the translational process so that new treatments and cures for disease can be delivered to patients faster.

Expert panel topics include: Best Practices for Building a High-Potential Company, Scientists and Engineers as Entrepreneurs, Raising Capital, Establishing and Building Ecosystems, Growing Pharmaceutical Manufacturing and R-D Cluster, and Partnering with Companies and Healthcare Systems. For the full agenda and speakers, visit: https://www.virginiacatalyst.org/agenda.html.

“The Virginia Catalyst and our major Virginia-based research universities, along with Virginia Bio are excited to host a major life sciences conference to share best practices and encourage collaborations. It is through this collaborative ecosystem that we are improving human health and further developing our life science economy by creating innovative companies, capital formation, and job creation,” said Michael Grisham, President & CEO, Virginia Catalyst.

To register: https://www.virginiacatalyst.org/registration.html

Recent News

02/01/2023

Engineered BioPharmaceuticals to Expand in Virginia

Governor Glenn Youngkin announced that Engineered BioPharmaceuticals, Inc., a pharmaceutical engineering and manufacturing company dedicated to advancing cost effective, state-of-the-art medicine, will invest $6.1 million to expand in the City of Danville. The company will expand from its current lab space in the Dan River Business Development Center into its first standalone manufacturing facility at

02/01/2023

Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced it has entered into an option agreement for the sale of the assets of Purnovate, Inc. (“Purnovate”), a wholly owned subsidiary of Adial, to Adenomed, LLC (“Adenomed”), a new company formed by Purnovate

01/31/2023

AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia

AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic pain syndromes, such as fibromyalgia. Revealed in the peer-reviewed journal Lupus Science and Medicine, the paper details AMPEL’s breakthrough approach to characterize the underlying disease activity from gene expression data obtained from patient blood samples. The FibroGENE® lab